The EMERALD trial (NCT03778931), is an open label phase 3 trial, investigating elacestrant, the first oral selective estrogen receptor degrader (SERD), against “standard of care”, in advanced or metastatic ER+/HER2- breast cancer patients [2]. Here, ESR1 is linked to breast carcinoma.